Breast Cancer Therapeutics in Major Developed Markets to 2020
Approval of Novel Therapies to Support Continued Dominance of HER2
Targeted Drugs
Research, the leading business intelligence provider, has released
its latest research: ‘Breast Cancer Therapeutics in Major Developed
Markets to 2020 – Approval of Novel Therapies to Support Continued
Dominance of HER2 Targeted Drugs ’, which provides indepth analysis
of breast cancer therapeutics market within the eight major
geographies of the US, Canada, the top five geographies in Europe
(the UK, France, Germany, Spain and Italy) and Japan. The report
provides an estimation of market size for 2013, along with market
forecast until 2020. It also covers disease epidemiology, treatment
algorithms, treatment patterns, indepth analysis of the pipeline,
and deal analysis. The breast cancer therapeutics market in the eight
major markets – The US, The UK, France, Germany, Spain, Italy, Japan
and Canada – was worth $9.2 billion in 2013, and is expected to grow
at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by
2020.
The US had the largest market in 2013, valued at $5.5 billion,
equivalent to a global share of 59%, followed by Japan with $871.5m
or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market
share and value of the leading eight at 2.9% and $268.4m, but is
expected to witness rapid growth over the forecast period with a CAGR
of 6.7%. This will only be surpassed by Japan, which is expected to
witness growth at a CAGR of 6.9%.
To Brows a Full Report with Toc: http://www.researchmoz.us/breast
cancertherapeuticsinmajordevelopedmarketsto2020approvalof
noveltherapiestosupportcontinueddominanceofher2targeted
drugsreport.html
Scope
The report analyzes treatment usage patterns, market
characterization, pipeline analysis and key licensing and co...